News

Filter

ThromboGenics gains rights to DME drug

06-09-2013

Belgium-based biopharma firm ThromboGenics (Euronext Brussels: THR:BR) has entered into a collaboration…

Bicycle TherapeuticsBiotechnologyDiabetesLicensingOphthalmicsPharmaceuticalThromboGenics

Roche returns rights to TB-403 to ThromboGenics and BioInvent, who abandon TB-402 development

05-06-2012

Belgium-based biopharma company ThromboGenics NV (Euronext Brussels: THR) and co-development partner…

BayerBioInventBiotechnologyLicensingOncologyOphthalmicsPharmaceuticalRocheTB-402TB-403ThromboGenicsXarelto

Novartis unit buys rights to ThromboGenics eye drug

16-03-2012

Belgian biopharma company ThromboGenics (Euronext Brussels: THR) revealed this morning that it has entered…

AlconBiotechnologyLicensingNovartisocriplasminOphthalmicsPharmaceuticalThromboGenics

COMPANY SPOTLIGHT

Menarini

Back to top